pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
PATH · news · pharmadog
← back to PATH
News mentioning PATH
183
stories
10d
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
biopharma dive
10d
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
biospace
11d
Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex
fiercebiotech
11d
aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug
fiercebiotech
13d
Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study
biospace
14d
Opinion: AI won’t enhance physician autonomy. It will further diminish it
stat
14d
Replimune wins FDA approval after melanoma drug was twice rejected
endpoints
14d
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
14d
FDA approves Moderna’s mRNA flu vaccine
biopharma dive
14d
Double shot of Vistagen’s anxiety nasal spray can’t beat placebo in ph. 2 trial
fiercebiotech
15d
CROs vs. biotechs: Finding the right fit
biospace
15d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
15d
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
15d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
15d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
16d
Vertex unfazed by competitive IgAN space as FDA verdict looms
biospace
17d
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
17d
STAT+: BioNTech names Guido Oelkers its new CEO
stat
18d
Convenience Kit Correction: Medical Action Industries Issues Correction for Kits Containing Recalled Namic Manifolds
fda medwatch
20d
Capricor CEO won’t rule out legal action against FDA after negative adcomm
biospace
21d
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
stat
22d
FDA reviewers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
22d
MapLight CEO on what investors missed in the biotech’s schizophrenia data
biopharma dive
22d
STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
stat
22d
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
biospace
23d
STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drug
stat
23d
Opinion: The VA could help America win the biotechnology race with China
stat
23d
STAT+: In the biotech industry, a most-wanted fugitive was long hiding in plain sight
stat
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
← prev
page 2 of 7
next →
